MorphoSys Appoints Head of Clinical Development
MorphoSys AG announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development.
Dr. Rojkjaer joins MorphoSys from Novartis Pharma AG where she most recently held the position of Head of Medical Affairs - Hematology, Europe, following her appointment as global clinical program head for Exjade®. Here she was responsible for all clinical activities in Europe for Novartis's Hematology portfolio including Gleevec® and Exjade®. Prior to her tenure at Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the Director of Global Medical Affairs Biopharmaceuticals and later Director, Clinical Development Hematology. During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US hematology portfolio amongst other accomplishments. Dr. Rojkjaer is a board certified hematologist and received her MD degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in hematology. She has held academic and hospital appointments in the US, Canada and Europe.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Novartis enters into agreement for exclusive US and Canadian rights to Fanapt, an FDA-approved oral therapy for schizophrenia

Distribution of COVID-19 vaccines with delivery drones - Wingcopter raises $22M to advance technology leadership in drone delivery, announces serial production
Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines
Cancer drug prevents build-up of toxic brain protein

Oriola-KD Corporation - Espoo, Finland
Evonik to double its L-lysine capacities in the U.S. - First additional quantities expected in November 2011

Boosting PET recycling with higher standards for laboratory experiments - New study shows how enzymatic plastic degradation could be brought one step closer to commercialisation

New device quickly detects harmful bacteria in blood - Tiny device could help professionals diagnose and fight deadly infections
